The Effect of Potassium Nitrate [KNO3] on Exercise Capacity in Heart Failure Patients.
-
- STATUS
- Recruiting
-
- participants needed
- 47
Summary
This study will test whether Potassium Nitrate (KNO3) will improve how people with HFpEF [Diastolic Heart Failure] can exercise. In HFpEF, patients are limited in their ability to do all the things they want to do, and exercise as much as they would like, due to becoming tired and short of breath early. We do not know exactly why these limitations occur. There is some evidence that in addition to problems with the heart, patients with HFpEF also have problems with their arteries and muscles that affect their ability to exercise. Potassium Nitrate has been shown to improve how muscles work and also improve blood flow to working muscles in the body in healthy individuals. We previously conducted a pilot study with our KNO3 pills and found them to be safe in subjects with HFpEF. We would like to now study our pills in a large study to see if we can improve exercise in HFpEF. The use of Potassium Nitrate in this study is experimental. Potassium Nitrate has not been approved by the Food and Drug Administration (FDA) for the use being evaluated in this study.
Description
If you decide to participate, you will be asked to come to the research center for 3 study visits and 2 MRI visits.Visit 1 confirms that you are a good candidate for our study. It will include baseline labs, questionnaires, arterial tonometry [non-invasive technique to measure pressure in the arteries], a resting echocardiogram, and a Six-Minute Walk Test. You will be mailed drug A [either KNO3 or placebo] and will begin taking it. You will come back 6 weeks later to the research center for visit 2 which includes labs, resting echocardiogram, arterial tonometry, MRI scan, and a maximal effort bike test. You will then be mailed drug B [either KNO3 or placebo] and will begin taking it. You will come back 6 weeks later to the research center for the 3rd and final visit. This includes the same testing as visit 2.
FAQ
- Contact: Jamie.Heier@uphs.upenn.edu, 609-961-1311 or Elizabeth.Proto@uphs.upenn.edu, 856-404-3786
Details
| Condition | Heart failure,Diastolic Heart Failure,heart failure,diastolic congestive heart failure (diagnosis),diastolic CHF,Diastolic (congestive) heart failure,diastolic congestive heart failure,diastolic congestive heart failure (diagnosis),Diastolic (congestive) heart failure,class II left-sided congestive heart failure,class III left-sided congestive heart failure (diagnosis) |
|---|---|
| Age | 18years - 90years |
| Clinical Study Identifier | N/A |
| Last Modified on | 19 February 2024 |
Eligibility
How to participate?
,
Send a message
Enter your contact details to connect with study team
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.